ALS/MND Research, Lambton College Collaboration, and a Holiday Message from Canurta

A Holiday Message from Canurta Therapeutics

As the year comes to a close, we at Canurta Therapeutics want to extend our heartfelt gratitude to all of our supporters, collaborators, and partners. 2024 has been a year of immense progress and we look forward to continuing this momentum in the year ahead, building meaningful connections and delivering impact where it’s needed most.

From all of us at Canurta, we wish you and your loved ones a joyful holiday season and a healthy, hopeful new year. Together, we can continue to make strides toward a brighter future.

Showcasing Research at the 35th International Symposium on ALS/MND

On December 7, 2024, Canurta Therapeutics presented its research at the 35th International Symposium on ALS/MND in Montreal, hosted by the Motor Neurone Disease (MND) Association.

Our poster presentation, "IVV-40: Therapeutic Potential of Cannabis-Derived Formulations in Mitigating Motor Neuron Disease," engaged an audience of academic leaders, industry experts, and patient communities.

The study demonstrated how our flagship CNR-400s series—standardized botanical formulations of polyphenols, cannabinoids, and terpenes—can target multiple ALS disease pathways, improving motor function and restoring neuronal health in ALS and frontotemporal dementia models.

Industry Insights: Canurta and Lambton College Collaboration

On December 12, 2024, Lambton College’s Bio-Industrial Process Research Centre (BPRC) hosted an Industry Insights session featuring Akeem Gardner, CEO of Canurta. Akeem shared insights into Canurta’s pioneering work harnessing rare cannabis-derived polyphenols, to develop targeted therapies for inflammation-related diseases. The session also highlighted Canurta’s collaboration with Lambton College to advance bioactivity research.

CEO, Akeem Gardner Featured on The Global Marketing Show

We are thrilled to share that our CEO, Akeem Gardner, was recently featured on The Global Marketing Show hosted by Wendy Pease. During the interview, Akeem highlighted how Canurta leverages global connections and diverse perspectives to drive growth, innovation, and impactful solutions in the biotech industry.

Listen now

Canurta's December Milestones

Research and Development

The Research and Development Team is investigating a new enzyme for the biosynthetic production of cannflavin B and other prenylated flavonoids.

Bioinformatics

Our molecular fingerprinting project advanced with new data integration, strengthening our pipeline to meet Pharmaceutical Quality - Chemistry, Manufacturing, and Controls (PQ/CMC) quality standards for consistent, high-quality formulations.